New drug cocktail shows promise in larynx cancer without surgery
NCT ID NCT04030455
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of two chemotherapy drugs (cisplatin and docetaxel) plus an immunotherapy drug (pembrolizumab) in 28 patients with stage II or III laryngeal cancer. The goal was to see if this drug-only approach could control the cancer and avoid the need for surgery or radiation, preserving the voice box. Early results showed a high rate of tumor shrinkage or disappearance, but long-term disease control and side effects are still being evaluated.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARYNGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Three-Pronged attack shrink Hard-to-Treat head and neck cancers?
- New CT scanner could sharpen view of throat cancer
- Remote hearing tests could save cancer Patients' hearing
- New hope for head and neck cancer: which drug works best with radiation?
- Experimental drug targets Hard-to-Treat cancers, but trial ends early
- New injection shrinks throat tumors before surgery?